New AML Guidance from BaFin and FIU
3. Dezember 2024
While it is getting cold outside, and everyone is preparing for the flu season of the year, the Commission is continuously and vigorously enforcing the bloc’s competition law in the pharmaceutical sector. The Commission’s recently published Update on Competition Enforcement in the Pharmaceutical Sector is a reminder that the pharmaceutical sector remains subject to intense antitrust scrutiny to ensure access to affordable and innovative drugs. What can pharmaceutical companies learn from recent abuse of dominance, cartel, merger control and State aid cases? Are stricter compliance rules needed to avoid running afoul of the antitrust rules and attracting the Commission’s attention?
